# Phase II Study to Evaluate the Combination of Rituximab and DepoCyte® in the C5R Chemotherapy Protocol in Patients Between the Ages of 18 and 60 Years With Primary Cerebral Non-Hodgkin Lymphoma and Systemic Diffuse Large B-cell Lymphoma With Neuromeningeal Invasion at Diagnosis

> **NCT00553943** · PHASE2 · COMPLETED · sponsor: **Lymphoma Study Association** · enrollment: 60 (actual)

## Conditions studied

- Lymphoma, Non-Hodgkin
- Diffuse Large B-cell Lymphoma

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Cytarabine

## Key facts

- **NCT ID:** NCT00553943
- **Lead sponsor:** Lymphoma Study Association
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2012-06
- **Final completion:** 2017-03
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2018-08-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00553943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00553943, "Phase II Study to Evaluate the Combination of Rituximab and DepoCyte® in the C5R Chemotherapy Protocol in Patients Between the Ages of 18 and 60 Years With Primary Cerebral Non-Hodgkin Lymphoma and Systemic Diffuse Large B-cell Lymphoma With Neuromeningeal Invasion at Diagnosis". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00553943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*